智通财经网·2025-06-03 02:29Group 1 - The core point of the news is that 康龙化成 (Pharmaron) has seen a stock increase of over 4% following the announcement of its investment in a healthcare fund [1] - 康龙化成's subsidiary, Pharmaron UK Limited, plans to invest $30 million in the BLC Healthcare USD Fund I L.P. as a limited partner [1][2] - The fund aims to raise approximately $100 million to invest in various securities and assets in the global biopharmaceutical and life sciences sectors, focusing on early and growth-stage projects for long-term capital appreciation [2] Group 2 - The investment will utilize the expertise of professional investment institutions in the biopharmaceutical industry [1] - The fund will have the discretion to invest in other investment funds or vehicles managed by third parties [2] - The investment strategy includes a wide range of securities, including equity, debt securities, and derivatives [2]